ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Argenx Announces Publication of Phase 3 ADAPT Trial Results of Efgartigimod for the Treatment of Generalized Myasthenia Gravis in The Lancet Neurology
June 17, 2021argenx (Euronext & Nasdaq: ARGX), today announced that The Lancet Neurology has published pivotal trial results from the Phase 3 ADAPT trial of efgartigimod, an FcRn antagonist, for the treatment of adults living with generalized myasthenia gravis (gMG).
Pharma Sources Insight January 2025
